Login / Signup

JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms.

Christina Schjellerup Eickhardt-DalbøgeHenrik Vedel NielsenKurt FuurstedChristen Rune StensvoldLee O' Brien AndersenBerit LiljeMorten Kranker LarsenLasse KjaerSarah Friis ChristensenTrine Alma KnudsenVibe SkovAnders Lindholm SørensenChristina EllervikLars Rønn OlsenJens Jørgen Elmer ChristensenXiaohui Chen NielsenHans Carl Carl HasselbalchAnna Cäcilia Ingham
Published in: European journal of haematology (2024)
The gut microbiota in MPN patients differs from HCs and is driven by JAK2V617F, whereas the gut microbiota in CALR patients resembles HCs more.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • prognostic factors
  • peritoneal dialysis
  • patient reported outcomes